Haemophilia A and haemophilia B: Molecular insights

Journal of Clinical Pathology - Molecular Pathology

Volumn 55, Issue 1, 2002, Pages 1-18

  Bowen, D J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRIN; MESSENGER RNA; MICROSATELLITE DNA; VON WILLEBRAND FACTOR;

CHROMOSOME INVERSION; CHROMOSOME REARRANGEMENT; CHROMOSOME XQ; DELETION MUTANT; DNA POLYMORPHISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENETIC LINKAGE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MISSENSE MUTATION; MOLECULAR GENETICS; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MUTATION; POLYMORPHISM, GENETIC;

EID: 0036164276     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.55.1.1     Document Type: Review

References (162)

1. Characterization of the human factor VIII gene
2. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)
3. The genetic linkage map of the human X chromosome
4. Physical mapping studies on the human X chromosome in the region Xq27-Xqter
5. Female twins with severe Christmas disease (hemophilia B)
6. Female haemophilia A in a family with seeming extreme bidirectional lyonization tendency: Abnormal premature X-chromosome inactivation?
7. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B
8. A transcribed gene in an intron of the human factor VIII gene
9. Evidence for a third transcript from the human factor VIII gene
10. Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctions
11. Sequence of the human factor VIII-associated gene is conserved in mouse
12. Expression of active human factor VIII from recombinant DNA clones
13. Structure of human factor VIII
14. Factor VIII and haemophilia A
15. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity
16. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease
17. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease
18. The effect of thrombin on the complex between factor VIII and von Willebrand factor
19. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex
20. The gene structure of human anti-haemophilic factor IX
21. Activation of human factor IX (Christmas factor)
22. Kinetics of the factor XIa catalyzed activation of human blood coagulation factor IX
23. The activation of factor IX by tissue factor-factor VII in a bovine plasma system lacking factor X
24. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation
25. Factor VIII structure and function
26. Factor IX
27. The life cycle of coagulation factor VIII in view of its structure and function
28. The molecular basis of haemophilia A and B
29. Hypervariable "minisatellite" regions in human DNA
30. Forensic application of DNA "fingerprints"
31. Human evolution
32. The context of human genetic evolution
33. Prenatal diagnosis of hemostatic disorders
34. Report of a joint WHO/WFH meeting on the control of haemophilia: Carrier detection and prenatal diagnosis
35. The sequence of the human genome
36. Initial sequencing and analysis of the human genome
37. Mutations and a polymorphism in the factor VIII gene discovered by denaturing gradient gel electrophoresis
38. Haemophilia A diagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene
39. Genetic mapping and diagnosis of haemophilia A achieved through a Bcll polymorphism in the factor VIII gene
40. A new Hindlll restriction fragment length polymorphism in the hemophilia A locus
41. A new polymorphism in the factor VIII gene for prenatal diagnosis of hemophilia A
42. Multiple Xbal polymorphisms for carrier detection and prenatal diagnosis of haemophilia A
43. A new polymorphism in the human factor VIII gene: Implications for linkage analysis in haemophilia A and for the evolution of int22h sequences
44. Haemophilia A diagnosis by analysis of a novel dinucleotide tandem repeat sequence within the factor VIII gene
45. Hemophilia A. Detection of molecular defects and of carriers by DNA analysis
46. Mspl polymorphism in the 3′ flanking region of the human factor VIII gene
47. A-793 G to A transition in the factor IX gene promoter is polymorphic in the Caucasian population
48. Use of a BamHI polymorphism in the factor IX gene for the determination of hemophilia B carrier status
49. An Msel RFLP in the 5′ flanking region of the factor IX gene: Its use for haemophilia B carrier detection in Caucasian and Thai populations
50. Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphisms
51. A second BamHI DNA polymorphism and haplotype association in the factor IX gene
52. Characterisation and use of an intragenic polymorphic marker for detection of carriers of haemophilia B (factor IX deficiency)
53. A new Mspl restriction fragment length polymorphism in the hemophilia B locus
54. The Malmo polymorphism of factor IX: Establishing the genotypes by rapid analysis of DNA
55. "Cryptic" dinucleotide polymorphism in the 3′ region of the factor IX gene shows substantial variation among different populations
56. Detection of polymorphisms at cytosine phosphoguanadine dinucleotides and diagnosis of haemophilia B carriers
57. Microsatellite evolution - Evidence for directionality and variation in rate between species
58. Spontaneous mutation rates to new length alleles at tandem-repetitive hypervariable loci in human DNA
59. The utility of a Hindlll polymorphism of factor VIII examined by rapid DNA analysis
60. Carrier detection in Japanese hemophilia A by use of three intragenic and two extragenic factor VIII DNA probes: A study of 24 kindreds
61. Restriction fragment length polymorphisms associated with factor VIII:C gene in Chinese
62. An effective route for the isolation of human genetic loci exemplified using the BgII restriction fragment length polymorphism of the factor VIII gene
63. Carrier testing strategy in haemophilia A
64. Linkage analysis in haemophilia A: Simultaneous genotyping of two polymorphisms of the human factor VIII gene using induced heteroduplex formation
65. Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX
66. Carrier testing in hemophilia B with an immunoassay that distinguishes a prevalent factor IX dimorphism
67. Determination of factor IX allotypes for carrier identification in haemophilia B
68. Segments containing alternating purine and pyrimidine dinucleotides: Patterns of polymorphism in humans and prevalence throughout phylogeny
69. Possible absence of common polymorphisms in coagulation factor IX gene in Japanese subjects
70. Diagnosis of hemophilia B carriers using two novel dinucleolide polymorphisms and Hha I RFLP of the factor IX gene in Japanese subjects
71. Common intragenic and extragenic polymorphisms of blood coagulation factors VIII and IX are different in Chinese and Caucasian populations
72. The varying frequencies of five DNA polymorphisms of X-linked coagulant factor IX in eight ethnic groups
73. Factor IX gene haplotypes in Brazilian blacks and characterization of unusual Ddel alleles
74. The factor IX BamHI polymorphism: T-to-G transversion at the nucleotide sequence -561. The BamHI/MSPI haplotypes in blacks and Caucasians
75. Laboratory methods for the genetic diagnosis of bleeding disorders
76. Intron 22-specific long PCR for the Xba I polymorphism in the factor VIII gene
77. Specific analysis of the intron 22 Xbal polymorphism of the human factor VIII gene using long-distance PCR
78. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays
79. DNA chip technology ante portas
80. Sequencing with microarray technology - A powerful new tool for molecular diagnostics
81. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin
82. X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B
83. Factor VIII-factar IX interactions: Molecular sites involved in enzyme-cofactor complex assembly
84. Region of factor IXa protease domain that interacts with factor VIIIa: Analysis of select hemophilia B mutants
85. Mutation databases on the Web
86. The skipping of constitutive exons in vivo induced by nonsense mutations
87. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes
88. Molecular diagnostics of 15 hemophilia A patients: Characterization of eight novel mutations in the factor VIII gene, two of which result in exon skipping
89. Mutagenic deamination of cytosine residues in DNA
90. Haplotype analysis of identical factor X mutants using PCR
91. "Founder" effect in different families with haemophilia B mutation
92. Factor IX and haemophilia B
93. Molecular genetics of coagulation factor VIII gene and hemophilia A
94. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A
95. Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions
96. Factor VIII gene inversions in severe hemophilia A: Results of an international consortium study
97. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A
98. A novel DNA inversion causing severe hemophilia A
99. Variant of intron 22 inversions in the factor VIII gene in severe hemophilia A
100. Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots
101. Nonsense and missense mutations in hemophilia A: Estimate of the relative mutation rate at CG dinudeotides
102. Mutations of factor VIII cleavage sites in hemophilia A
103. The molecular genetic analysis of hemophilia A: A directed search strategy for the detection of point mutations in the human factor VIII gene
104. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene
105. Molecular pathology of haemophilia B
106. Recurrent nonsense mutations at arginine residues cause severe hemophilia B in unrelated hemophiliacs
107. The incidence and distribution of CpG→TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots
108. Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain
109. Three distinct point mutations in the factor IX gene of three Japanese CRM+ hemophilia B patients (factor IX BMNagoya 2, factor IX Nagoya 3 and 4)
110. Mutations in hemophilia Bm occur at the Arg 180-Val activation site or in the catalytic domain of factor IX
111. Identification of the molecular defect in factor IX Chapel Hill: Substitution of histidine for arginine at position 145
112. Factor IX Albuquerque (arginine 145 to cysteine) is cleaved slowly by factor XIa and has reduced coagulant activity
113. Functional consequences of an arginine 180 to glutamine mutation in factor IX Hilo
114. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain
115. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
116. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor
117. A novel cause of mild/moderate hemophilia A: Mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor
118. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor
119. Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNA
120. Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII
121. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
122. New variant of von Willebrand disease with defective binding to factor VIII
123. Von Willebrand disease masquerading as haemophilia A
124. Intracellular accumulation of factor VIII induced by missense mutations Arg593→Cys and Asn618→Ser explains cross-reacting material-reduced haemophilia A
125. Mapping of monoclonal antibodies to human factor IX
126. Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX
127. 2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X
128. The role of amino-terminal residues of the heavy chain of factor IXa in the binding of its cofactor, factor VIIIa
129. Missense mutations at ALA-10 in the factor IX propeptide: An insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy
130. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX
131. Effect of propeptide mutations on post-translational processing of factor IX. Evidence that beta-hydroxylation and gamma-carboxylation are independent events
132. Vitamin K dependent modifications of glutamic acid residues in prothrombin
133. Isolation of the human gamma-carboxylase and a gamma-carboxylase-associated protein from factor IX-expressing mammalian cells
134. Changes in phylloquinone epoxidase activity related to prothrombin synthesis and microsomal clotting activity in the rat
135. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism
136. Recovery from hemophilia B Leyden: An androgen-responsive element in the factor IX promoter
137. Hemophilia B Leyden: A sex-linked hereditary disorder that improves after puberty
138. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B
139. Further evidence for the importance of an androgen response element in the factor IX promoter
140. Molecular characterization of mild-to-moderate hemophilia A: Detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis
141. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate)
142. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: Identification of 14 novel mutations
143. Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene
144. Direct detection of point mutations by mismatch analysis: Application to haemophilia B
145. Haemophilia B mutations in a complete Swedish population sample: A test of new strategy for the genetic counselling of diseases with high mutational heterogeneity
146. First report on UK database of haemophilia B mutations and pedigrees
147. Start of UK confidential haemophilia A database: Analysis of 142 patients by solid phase fluorescent chemical cleavage of mismatch
148. Ultrarapid mutation detection by multiplex, solid-phase chemical cleavage
149. Fast and efficient mutation detection method using multiplex PCR and cycle sequencing - Application to haemophilia B
150. A genetic view on the etiology of the inhibitor complication
151. The genetic basis of inhibitor development in haemophilia A
152. Haemophilia A: Mutation type determines risk of inhibitor formation
153. Molecular biological aspects of inhibitor development
154. Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22
155. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A
156. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII
157. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype
158. Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene
159. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein
160. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism
161. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice
162. Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein